BRPI0413767A - pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof - Google Patents

pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof

Info

Publication number
BRPI0413767A
BRPI0413767A BRPI0413767-1A BRPI0413767A BRPI0413767A BR PI0413767 A BRPI0413767 A BR PI0413767A BR PI0413767 A BRPI0413767 A BR PI0413767A BR PI0413767 A BRPI0413767 A BR PI0413767A
Authority
BR
Brazil
Prior art keywords
pharmaceutical
solvate
pharmaceutical formulation
salt
pharmaceutical product
Prior art date
Application number
BRPI0413767-1A
Other languages
Portuguese (pt)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BRPI0413767A publication Critical patent/BRPI0413767A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PRODUTO FARMACêUTICO OU FORMULAçãO FARMACêUTICA, PROCESSO PARA PREPARAR UM PRODUTO FARMACêUTICO OU FORMULAçãO FARMACêUTICA, MéTODO PARA TRATAR UMA DOENçA E USO DE PELO MENOS UMA ARTEMISININA OU UM SAL, SOLVATO OU DERIVADO DESTA. A presente invenção compreende uma composição farmacêutica para tratar malária incluindo pelo menos uma artemisinina ou um sal, solvato ou derivado desta, e pelo menos uma quinolina ou um sal, solvato ou derivado desta, na forma de uma preparação combinada, para uso simultâneo ou separado no tratamento da malária.PHARMACEUTICAL PRODUCT OR PHARMACEUTICAL FORMULATION, PROCESS FOR PREPARING A PHARMACEUTICAL PRODUCT OR PHARMACEUTICAL FORMULATION, A METHOD FOR TREATING A DISEASE AND THE USE OF AT LEAST ARTEMISININ OR SALT, SOLVATE OR DERIVATED. The present invention comprises a pharmaceutical composition for treating malaria comprising at least one artemisinin or a salt, solvate or derivative thereof, and at least one quinoline or a salt, solvate or derivative thereof in the form of a combined preparation for simultaneous or separate use. in the treatment of malaria.

BRPI0413767-1A 2003-09-04 2004-09-03 pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof BRPI0413767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN902MU2003 2003-09-04
PCT/GB2004/003748 WO2005023304A2 (en) 2003-09-04 2004-09-03 Antimalarial compositions and manufacturing process thereof

Publications (1)

Publication Number Publication Date
BRPI0413767A true BRPI0413767A (en) 2006-10-31

Family

ID=34259970

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413767-1A BRPI0413767A (en) 2003-09-04 2004-09-03 pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof

Country Status (4)

Country Link
AP (1) AP2006003557A0 (en)
BR (1) BRPI0413767A (en)
WO (1) WO2005023304A2 (en)
ZA (1) ZA200602031B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0401107A (en) * 2004-04-13 2005-11-22 Fundacao Oswaldo Cruz Compounds derived from artesunate, process of preparing these compounds, pharmaceutical composition containing said compounds, use of the respective medicine in the treatment or prevention of malaria or other parasitic diseases and therapeutic method
FR2884715B1 (en) * 2005-04-20 2007-06-15 Sanofi Aventis Sa ASSOCIATION BETWEEN FERROQUIN AND AN ARTEMISININE DERIVATIVE FOR THE TREATMENT OF MALARIA
WO2007036947A1 (en) * 2005-09-30 2007-04-05 Ipca Laboratories Limited Delayed release anti-malarial composition
WO2007043061A1 (en) * 2005-10-11 2007-04-19 Ipca Laboratories Ltd. Anti-malarial combination and methods of formulation
CH696229A5 (en) * 2006-05-13 2007-02-28 Professeur Dr Achille Benakis Antimalarial composition in geometrical solid tablet form obtained by the compression of a medicine powder and excipients, useful to treat malaria, comprises three separate layers
FR2914860B1 (en) * 2007-04-12 2009-05-22 Ile D Inventeurs Apis Spheromo MULTILAYER SPHEROIDS WITH ANTIPALUDITIC ACTION IN WHICH ONE OF THE LAYERS CONTAINS ARTESUNATE
CN101756982B (en) * 2008-12-17 2012-07-04 重庆医药工业研究院有限责任公司 Artesunate compound medicine composition with improved mouth feeling and high stability
FR2951945B1 (en) * 2009-11-05 2013-08-09 Sanofi Aventis PHARMACEUTICAL COMPOSITION
WO2015041722A1 (en) * 2013-09-17 2015-03-26 Kryptonite Group, Ltd Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
TWI733649B (en) * 2014-03-07 2021-07-21 巴哈馬商克利普頓集團公司 Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
US20170326102A1 (en) * 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
CN107982227A (en) * 2017-12-05 2018-05-04 昆药集团股份有限公司 A kind of tablet of dihydroartemisinine and preparation method thereof
CN107982228B (en) * 2017-12-05 2022-08-16 昆药集团股份有限公司 Dihydroartemisinin tablet and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3019169A (en) * 1958-06-23 1962-01-30 Sterling Drug Inc Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process
US5219865A (en) * 1987-05-08 1993-06-15 Hoechst Aktiengesellschaft Pharmaceutical combination for the prophylaxis and therapy of malaria
DE68906345T2 (en) * 1988-10-07 1993-10-28 Hoechst Ag Antimalarial compositions utilizing quinidine, artemisinin and their derivatives.
CN1058717A (en) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 New antimalarial agent-Coartem and preparation method thereof
DE60229440D1 (en) * 2002-02-13 2008-11-27 Mepha Ltd COMPOSITION OF ARTHROUSATE AND MEQUOQUIN FOR THE TREATMENT OF MALARIA

Also Published As

Publication number Publication date
AP2006003557A0 (en) 2006-04-30
ZA200602031B (en) 2007-05-30
WO2005023304A3 (en) 2005-07-07
WO2005023304A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
BRPI0513050A (en) perimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof, process for the preparation thereof, pharmaceutical composition, use of a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof, and, method for producing an antiproliferative effect on a warm-blooded animal
BRPI0416801A (en) 1h-imidazoquinoline derivatives as protein synase inhibitors
BRPI0413767A (en) pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof
BRPI0513058A (en) pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof, process for the preparation thereof, pharmaceutical composition, use of a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof, and, method for producing an antiproliferative effect on a warm-blooded animal
AR029175A1 (en) 2-AMINO-PHENYLPURINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT
BR0016935A (en) Use of fumaric acid derivatives for treatment of mitochondrial diseases
BRPI0416796A (en) organic compounds
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
BRPI0510778A (en) pharmaceutical composition, process for preparing it, method for treating rhinitis, and use of a composition
BR0309167A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject affected by a pathological condition or disease and combination product
BRPI0717907A2 (en) "COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING A CANCER, INHIBITING OR MODULATING LIPID KINASE ACTIVITY, PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND KIT"
BRPI0517634A (en) thiazole derivative or a pharmaceutically acceptable derivative thereof, process for preparing a compound, pharmaceutical composition, use of a compound or pharmaceutically acceptable salt thereof, and method of treating a disease or condition
BRPI0410117A (en) compound, pharmaceutical composition, method for treating a jak3-mediated disease or condition, and process for preparing a compound
DE60238999D1 (en) AMINOINDAZONE DERIVATIVES WITH KINASEINHIBIERING EFFECT, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
BRPI0409427A (en) compound, use thereof, pharmaceutical composition, method of treating a human suffering from a hyperproliferative disease, and process for the preparation of a compound or a pharmaceutically acceptable salt, ester or prodrug thereof
BR0212484A (en) Compound, process for the preparation and use thereof, method of treating eating disorders in a warm-blooded animal, and pharmaceutical composition
BR122019010200B8 (en) pyrazole-quinazoline compounds, their salts, products or kits and pharmaceutical compositions
BRPI0418351A (en) compound or a pharmaceutically acceptable salt thereof, methods of limiting cell proliferation in a human or animal, treating a human or animal suffering from cancer, treating cancer prophylaxis, treating a human or animal suffering from a disease treatment of a human or animal suffering from a proliferative cancer treatment disease, for the treatment of cancer-associated infections, for the prophylactic treatment of cancer-associated infections, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, method of inhibiting chk1 kinase, and process for preparing a compound or a pharmaceutically acceptable salt thereof
BRPI0508177A (en) compound, process for the production of compound, pharmaceutical composition, use of compound method for treating a disease and combination product
BR0113358A (en) Quinazoline derivative or a pharmaceutically acceptable salt thereof, process for its preparation, pharmaceutical composition, and use of the derivative or pharmaceutically acceptable salt thereof
BRPI0612109A2 (en) compound, methods of treating or preventing a disease, pharmaceutical formulation, and process for preparing a compound
BRPI0507071A (en) pyrazol [1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
BRPI0411017A (en) 3-substituted indoles and derivatives thereof as therapeutic agents
BRPI0517032A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or preventing diseases and using such compounds

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]